Prognosis

A mesothelioma diagnosis comes with many important questions. Perhaps the most crucial question is – what is the prognosis? In fact, the prognosis of mesothelioma varies depending on a number of variables. These variables include:

1. The patient – their age, biology, and state of health
2. The cancer – has the mesothelioma spread or is it localized when it is diagnosed and what is the cell type
3. The treatment or treatments selected
4. The expertise of the treatment team (doctors and other clinicians)

The Patient’s Health

A patient’s general state of health is an important prognostic factor in fighting any disease and mesothelioma is no exception. In addition, a patient’s biology or physiology also plays a role. For example, will chemotherapy work or can it be tolerated? Does the patient have a heart condition so that surgery is not an option? How will the patient’s biology interact with the treatment? The answers to these questions can all play a role in the prognosis.

The Cancer

The spread or lack of spread of the cancer is also an important factor. If mesothelioma is localized it can be easier to treat. In fact, surgery is usually only an option if the cancer has not metastasized. If it has spread then treatment options may be more limited. In addition, there are three cell types of mesothelioma – epithelioid, biphasic, and sacramatoid. The first, epithelioid, often has the best prognosis of the three.

The Treatment

The treatment or therapies selected is also important. Patients can select from conventional therapies (radiation, chemo, and surgery), clinical trials or integrative or alternative modalities. Not every therapy works in every patient. There is an important connection between a person’s physiology, cancer and the treatments selected. The interchange or intersection of these three factors often dictate what the treatment outcome and prognosis will be. Unfortunately, it is often difficult to predict because how a tumor or a treatment acts in a patient’s body is often not known until after the fact.

The Doctors’ Expertise

The last factor is the expertise of your doctors or licensed care givers. How these people do their jobs can be a key factor in prognosis. Are the surgeons experienced with mesothelioma? For example, what is their mortality rate for surgery? The smallest rate bodes better than the highest rate. Also, what options can these treaters suggest? Do they only offer chemo or can they offer a wide range of different modalities and treatment options. All these factors play a role in the prognosis of mesothelioma.

Below are some more details about the prognosis for mesothelioma.

Prognosis of Pleural Mesothelioma

The prognosis of pleural mesothelioma with standard treatment is typically not great.   Median overall survival is a little over a year.  However, there are a number of factors that affect prognosis.

A number of studies have been performed over the years to determine what treatments are optimum for mesothelioma and what factors lead to a better prognosis. Below, we report on several of these.

In a September 2016 Austrian study, a total of 210 patients with malignant pleural mesothelioma were followed.

• 167 (79.5%) were men and 43 (20.5%) were women
• The average age was 67 at the time of diagnosis
• Asbestos exposure was confirmed in 109 (69.4%) patients
• The majority of patients had epithelioid cell type (67.2%)
• Sarcomatoid comprised 16 (7.6%)
• Biphasic was found in 28 patients (13.3%)
• In 25 patients, the cell type was not specified

Data about survival was available for 185 patients. The study found:

• Median overall survival was 19.1 months.
• Pleural mesothelioma patients with early-stage disease (stages I, II) had an overall survival of 26.4 months.
• Pleural mesothelioma patients with late-stage disease (stages III, IV) had an overall survival of 13.0 months .
• Patients with epithelioid cell type had overall survival of 25.1 months.
• Patients with sarcomatoid or biphasic cell type had overall survival of 10.2 months.
• There was no survival difference between males and females.
• There was no survival difference between patients below or above the age of 65 years.
• Survival was significantly better in patients undergoing surgery. However, these patients were significantly younger, had earlier-stage disease, better performance status, and more often had epithelioid subtype.

The study concluded that factors that indicated a better prognosis included: higher Karnofsky score, earlier stage disease, epithelioid cell type, and surgery within multimodality treatment.

• Management of malignant pleural mesothelioma – part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database. Klikovits T, et al., Wien Klin Wochenschr. 2016 Sep;128(17-18):627-34.

Prognosis of Peritoneal Mesothelioma

The prognosis of peritoneal mesothelioma has become much better with the advent of surgery and HIPEC.  The following studies illustrate the improvements in prognosis over the last several years.

Peritoneal Mesothelioma Prognosis with Chemotherapy

In a 2011 Greek Study, chemotherapy was used to treat peritoneal mesothelioma patients.  Six patients with peritoneal mesothelioma were treated with 6 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2). Chemotherapy was administered on an outpatient basis every 3 weeks. The estimated median overall survival was 24 months.

• Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. Lainakis G, et al., Tumori. 2011 Jan-Feb;97(1):25-9.

Peritoneal Mesothelioma Prognosis with HIPEC

An April 2014 United States Study examined 65 patients with pleural mesothelioma who underwent surgery and HIPEC (hyperthermic intraperitoneal chemoperfusion) between 2001 and 2010.

What is HIPEC for Mesothelioma?

HIPEC is where heated chemotherapy is used to bath the surgical cavity putting the chemo in direct contact where the tumor cells remain.  The study found that overall mesothelioma survival was 46.2 months.  The study also found that although survival was better, there were side effects associated with this treatment approach that included:

• Six percent of the patients died within 60 days.
• Of the 65 patients, 91 % were admitted to the intensive care unit (ICU) postoperatively, with median hospital length of 12 days.
• A total of 12 patients (18 %) underwent reoperation: four patients (33 %) for enteric leak, 1 patient (8 %) for an intra-abdominal abscess, and seven patients (58%) for other reasons.

Factors that contributed to a poor prognosis included:

• Older patient
• More widespread tumors
• More aggressive cell type
• Incomplete surgery
• Post-operative infection

The study concluded that better prognosis is associated with patients who have the epithelioid cell type, lower volume of tumor, and more effective surgery (most tumor removed).

• Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Magge D., et al., Ann Surg Oncol. 2014 Apr;21(4):1159-65.

Next: Treatment

Related Posts

Advanced Computer Program Might Pinpoint Mesothelioma Sooner - Scientists at New York University School of Medicine have successfully used a sophisticated computer program to distinguish between different types of lung cancer and identify the mutated genes behind them. The developers say the technology could open the door to faster diagnosis of other types of cancer, including malignant mesothelioma. Malignant Mesothelioma, the Asbestos Cancer Malignant pleural mesothelioma is a form of lung cancer caused by asbestos exposure. Instead of starting in the lung tissue like other types of lung cancer, it grows on the membrane that surrounds the lungs and can then spread to the lungs and other organs. There is no cure and the prognosis for mesothelioma is usually poor. As with most types of cancer, earlier diagnosis … Continue reading Advanced Computer Program Might Pinpoint Mesothelioma Sooner »

Mobile App Could Help Mesothelioma Patients Find New Treatments - Mesothelioma patients now have a high-tech new way to connect with cutting edge mesothelioma treatments around the world – for a price. A pair of Harvard-trained oncologists have just rolled out a new app that promises to connect people who have cancers like pleural mesothelioma with treatments and clinical trials that even their physicians may not be aware of. The app, called Driver, is being rolled out this week in the US and China in the wake of a trial run with a hundred people over the past year. How Might Driver Help Mesothelioma Patients? One of the biggest obstacles faced by patients diagnosed with rare cancers like pleural or peritoneal mesothelioma is getting the most up-tp-date information about potential … Continue reading Mobile App Could Help Mesothelioma Patients Find New Treatments »

Muscle Loss May Predict Peritoneal Mesothelioma Survival - Age-related muscle loss appears to be an independent predictor of peritoneal mesothelioma survival after surgery. The news might help patients and doctors make better treatment decisions. Researchers at the Lyon-Sud Hospital Center in Lyon say they have found a connection between sarcopenia—muscle loss associated with aging—and how long people with peritoneal mesothelioma (or another abdominal condition called pseudomyxoma peritonei) survive after cytoreductive surgery. The bottom line: The less muscle loss, the longer a mesothelioma patient is likely to survive. CRS/HIPEC Surgery for Mesothelioma Cancer Both peritoneal mesothelioma and pseudomyxoma peritonei (PMP) are cancers that grow in the abdomen. Like other types of malignant mesothelioma, peritoneal mesothelioma is associated with exposure to asbestos. It is typically a fast-growing cancer for which … Continue reading Muscle Loss May Predict Peritoneal Mesothelioma Survival »

Study Predicts New Mesothelioma Therapies on the Horizon - A new article published by a pair of UK scientists predicts a brighter future for mesothelioma patients thanks to a growing understanding of the disease and how to treat it. Malignant mesothelioma is the cancer most closely associated with asbestos. Although only a small percentage of asbestos-exposed people go on to develop mesothelioma, those who do face a grim prognosis. Doctors learned early on that standard cancer treatments rarely work for patients with mesothelioma. But Anna Bibby and Nick Maskell with Bristol Medical School and the North Bristol Lung Centre say the large amount of high-quality mesothelioma research conducted in the last decade has moved medicine closer to finding a cure for this intractable cancer. Important Mesothelioma Research Findings In … Continue reading Study Predicts New Mesothelioma Therapies on the Horizon »

Mesothelioma Tumors Thrive in Low Oxygen Environment - South Korean researchers have uncovered a clue that might help explain why mesothelioma tumors are so aggressive — and what can be done to counter that aggression. The new study centers on hypoxia, a deficiency in the amount of oxygen reaching the tissues. It is a hallmark of many types of solid tumors and it turns out that malignant mesothelioma tumors are no exception. Patients with these hypoxic tumors tend to worsen quickly, be less responsive to treatment, and end up with poor outcomes. The Effect of Oxygen on Malignant Mesothelioma Scientists in the Laboratory of Clinical Pathology, College of Veterinary Medicine, Seoul National University are trying to better understand how hypoxia effects human malignant mesothelioma cells and exactly what … Continue reading Mesothelioma Tumors Thrive in Low Oxygen Environment »

Study Confirms Feasibility and Safety of Minimally Invasive Mesothelioma Surgery - New research suggests that the future of surgery for peritoneal mesothelioma could be much less invasive than it is now—at least for select patients. The study focused on patients with tumors that had spread to the peritoneal membrane that lines the abdomen. This is the place where malignant mesothelioma starts. In a report published in the journal Surgical Endoscopy, an international team of experts concludes that minimally invasive surgery for peritoneal cancers like malignant mesothelioma is both feasible and safe and should be considered for certain patients. CRS/HIPEC Standard of Care for Malignant Mesothelioma Currently, the standard of care for peritoneal mesothelioma is cytoreductive surgery to remove as much of the tumor as possible followed by a rinse of heated … Continue reading Study Confirms Feasibility and Safety of Minimally Invasive Mesothelioma Surgery »

Mesothelioma Diagnosis: Lung Fluid Testing Has its Limits - Lung fluid tests for malignant mesothelioma are accurate less than half the time according to cancer researchers at Australia’s Royal Melbourne Hospital. The production of excess lung fluid (pleural effusions) is a common side effect of mesothelioma, as well as a number of other malignant and non-malignant conditions. In mesothelioma patients, this buildup of fluid often leads to breathlessness and chest pain. Because this fluid can contain cells from a growing tumor, doctors have used lung fluid testing, also known as cytologic analysis, to identify certain types of cancer, including pleural mesothelioma. But a new study published in the Internal Medicine Journal suggests that, especially with mesothelioma, lung fluid testing is only moderately effective and must be combined with other … Continue reading Mesothelioma Diagnosis: Lung Fluid Testing Has its Limits »

Mesothelioma Outcomes Better at High Volume Facilities - A new study provides more evidence that malignant pleural mesothelioma patients considering surgery would do well to seek out a facility that does a lot of them. Researchers found that mesothelioma patients tend to have fewer complications and shorter hospital stays when they are treated at high volume facilities. The new study is based on data from the National Cancer Database and is published in the latest issue of the journal Lung Cancer. It defines a “high volume facility” as a medical facility that falls into the 90th percentile in terms of the number of pleural mesothelioma surgeries done there. All other facilities were classified as lower volume facilities (LVFs). HVFs vs LVFs for Mesothelioma Treatment Of the 1307 mesothelioma … Continue reading Mesothelioma Outcomes Better at High Volume Facilities »

Mesothelioma Patients May Benefit From Kindness, Study Reveals - A study of more than 400 patients and their families shows that people coping with cancers such as malignant mesothelioma do better when their medical caregivers show them kindness. The study was originally published in the Journal of Oncology Practice and identifies six specific types of kindness that can help to ease the pain and challenges of mesothelioma treatment. High Tech Must Be Balanced by “High Touch” In the introduction to the report, Dr. Leonard Berry, a University Distinguished Professor of Marketing at Texas A&M University, says high tech therapies for mesothelioma and other cancers  should be balanced by “high touch” from caregivers. “Simple kindness can help to diffuse negative emotions that are associated with cancer diagnosis and treatment—and may … Continue reading Mesothelioma Patients May Benefit From Kindness, Study Reveals »

What Type of Mesothelioma Do I Have? CT May Be Able to Tell - Researchers from one of the country’s top cancer centers say it may be possible to tell what subtype of pleural mesothelioma a person has by using computed tomography (CT). Pleural mesothelioma is an aggressive lung-related cancer for which patients and their doctors must develop a treatment plan quickly to get ahead of the disease. The challenge is that, not only is mesothelioma highly resistant to standard cancer treatment, but different subtypes of mesothelioma are often managed with different drugs and therapies. The new study from Memorial Sloan Kettering Cancer Center in New York suggests that CT may offer an accurate and non-invasive way to classify mesothelioma patients which could speed the treatment planning process and lead to longer mesothelioma survival. … Continue reading What Type of Mesothelioma Do I Have? CT May Be Able to Tell »